Enrollment Progressing Quickly in PolarisDMD Trial Testing Edasalonexent, Catabasis Says

Enrollment is progressing quickly in Catabasis Pharmaceuticals‘ pivotal Phase 3 PolarisDMD trial, testing its investigational small molecule therapy edasalonexent for Duchenne muscular dystrophy (DMD) — with sites in some countries already full, the company said. Screening is ongoing in the U.S., Canada, Australia, the U.K.,…